These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18342102)

  • 41. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
    Bhojani N; Jeldres C; Patard JJ; Perrotte P; Suardi N; Hutterer G; Patenaude F; Oudard S; Karakiewicz PI
    Eur Urol; 2008 May; 53(5):917-30. PubMed ID: 18054825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
    Feldt S; Schüssel K; Quinzler R; Franzmann A; Czeche S; Ludwig WD; Schulz M
    Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Reilly LM; Gerami P; Guitart J
    Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 45. [Comments on the article "Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib"].
    Wolf G
    Hautarzt; 2011 Jul; 62(7):560; author reply 561-4. PubMed ID: 21720940
    [No Abstract]   [Full Text] [Related]  

  • 46. Sorafenib: muscle wasting.
    Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
    Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sorafenib: atypical cutaneous side effects.
    Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
    Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
    [No Abstract]   [Full Text] [Related]  

  • 49. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
    Ravaud A; Digue L; Trufflandier N; Smith D
    Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
    [No Abstract]   [Full Text] [Related]  

  • 50. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    Vaklavas C; Lenihan D; Kurzrock R; Tsimberidou AM
    Oncologist; 2010; 15(2):130-41. PubMed ID: 20139170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Schutz FA; Je Y; Richards CJ; Choueiri TK
    J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    Girardi F; Franceschi E; Brandes AA
    Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
    Overkleeft EN; Goldschmeding R; van Reekum F; Voest EE; Verheul HM
    Ann Oncol; 2010 Jan; 21(1):184-5. PubMed ID: 19889617
    [No Abstract]   [Full Text] [Related]  

  • 55. Sorafenib-induced eruptive melanocytic lesions.
    Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
    Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
    [No Abstract]   [Full Text] [Related]  

  • 56. [New drugs; sunitinib and sorafenib].
    Bellersen L
    Ned Tijdschr Geneeskd; 2008 Feb; 152(8):469-70; author reply 470. PubMed ID: 18363211
    [No Abstract]   [Full Text] [Related]  

  • 57. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 58. Sorafenib: gastrointestinal perforation. Known reactions to VEGF inhibitors.
    Prescrire Int; 2009 Apr; 18(100):69. PubMed ID: 19585726
    [No Abstract]   [Full Text] [Related]  

  • 59. Erythema multiforme-like drug reaction to sorafenib.
    Lewin J; Farley-Loftus R; Pomeranz MK
    J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
    King CR
    ONS News; 2006; 21(8 Suppl):57-8. PubMed ID: 16925154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.